Literature DB >> 19395123

Primary hyperhidrosis increases the risk of cutaneous infection: a case-control study of 387 patients.

Hobart W Walling1.   

Abstract

BACKGROUND: Although primary hyperhidrosis (PHH) has been frequently associated with diminished quality of life, the medical consequences of the condition are less well studied.
OBJECTIVE: The objective was to study the clinical presentation of PHH and to determine its relationship to cutaneous infection.
METHODS: A retrospective case-control study of patients encountered between 1993 and 2005 with the International Classification of Diseases, Ninth Revision diagnosis code for hyperhidrosis (HH) and meeting criteria for PHH was conducted.
RESULTS: Of 387 patients with PHH included, 59% were female and 41% were male; mean age was 27.3 years (range 2-72). Sites of HH included soles (50.1%), palms (45.2%), and axillae (43.4%). Distributional patterns of HH were isolated axillary (27.6%), palmoplantar (24.3%), isolated plantar (15%), axillary/palmoplantar (5.7%), isolated palmar (5.7%), and craniofacial (5.2%). Axillary HH was more common in female patients (P = .004). The mean age of onset (18.6 +/- 12.3 years) indicated a mean duration of untreated symptoms of 8.9 years. Age at onset for palmoplantar HH (11.5 +/- 8 years) was significantly younger than for axillary HH (20.0 +/- 8.3 years; P < .0001), whereas onset of craniofacial HH (25.4 +/- 13.7 years) was older (P < .001). Exacerbating factors included stress/emotion/anxiety (56.7%) and heat/humidity (22%). The overall risk of any cutaneous infection was significantly (P < .0001) increased in HH compared with controls (odds ratio [OR] 3.2; 95% confidence interval [CI] 2.2-4.6). Site-specific risks of fungal infection (OR 5.0; 95% CI 2.6-9.8; P < .0001), bacterial infection (OR 2.6; 95% CI 1.2-5.7; P = .017), and viral infection (OR 1.9; 95% CI 1.2-3.0; P = .011) were all increased. Risks of pitted keratolysis (OR 15.4; 95% CI 2.0-117; P = .0003), dermatophytosis (OR 9.8; 95% CI 3.4-27.8; P < .0001), and verruca plantaris/vulgaris (OR 2.1; 95% CI 1.3-3.6; P = .0077) were particularly increased. Association with atopic/eczematous dermatitis (OR 2.9; 95% CI 1.5-55; P = .019) was observed. LIMITATIONS: Retrospective design and single-institution study are limitations.
CONCLUSIONS: Patients with HH are at high risk of secondary infection. Management of HH may have a secondary benefit of decreasing this risk.

Entities:  

Mesh:

Year:  2009        PMID: 19395123     DOI: 10.1016/j.jaad.2009.02.038

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  11 in total

1.  Long-term results of oxybutynin treatment for palmar hyperhidrosis.

Authors:  Nelson Wolosker; Marcelo Passos Teivelis; Mariana Krutman; Rafael P de Paula; José R M de Campos; Paulo Kauffman; Pedro Puech-Leão
Journal:  Clin Auton Res       Date:  2014-11-27       Impact factor: 4.435

2.  Quality of life after endoscopic lumbar sympathectomy for primary plantar hyperhidrosis.

Authors:  Roman Rieger; Sonja Pedevilla; Johannes Lausecker
Journal:  World J Surg       Date:  2015-04       Impact factor: 3.352

3.  The efficacy and safety of a fractional microneedle radiofrequency device for the treatment of axillary hyperhidrosis: clinical prospective pilot study.

Authors:  Joon Min Jung; Hyoung Min Na; Jung Ho Kim; Jihae Yoon; Hee Joo Yang; Woo Jin Lee; Sung Eun Chang; Mi Woo Lee; Chong Hyun Won
Journal:  Lasers Med Sci       Date:  2021-08-28       Impact factor: 3.161

Review 4.  Treatment of Hyperhidrosis: An Update.

Authors:  Mattias A S Henning; Dorra Bouazzi; Gregor B E Jemec
Journal:  Am J Clin Dermatol       Date:  2022-07-01       Impact factor: 6.233

5.  Hyperhidrosis Comorbidities and Treatments: A Register-based Study among 511 Subjects.

Authors:  Sanna-Liisa Heiskanen; Jani Niskala; Jari Jokelainen; Kaisa Tasanen; Laura Huilaja; Suvi-Päivikki Sinikumpu
Journal:  Acta Derm Venereol       Date:  2022-02-28       Impact factor: 3.875

6.  Is Climate Associated With Revision for Prosthetic Joint Infection After Primary TKA?

Authors:  Ben Parkinson; Drew Armit; Peter McEwen; Michelle Lorimer; Ian A Harris
Journal:  Clin Orthop Relat Res       Date:  2018-06       Impact factor: 4.176

7.  Hyperhidrosis Prevalence: A Disease Underreported by Patients and Underdiagnosed by Physicians.

Authors:  Surajsingh Wadhawa; Sudha Agrawal; Manoj Chaudhary; Sanjib Sharma
Journal:  Indian Dermatol Online J       Date:  2019-11-01

8.  Safety of Radiofrequency Ablation of Thoracic T2 and T3 Sympathectomy in Palmar Hyperhidrosis: A Case Report.

Authors:  Atef Mohammad Khalil; Joseph Makram Botros; Maged Labib Boules; Atef Kamel Salama; Safaa Gaber Ragab
Journal:  Anesth Pain Med       Date:  2021-07-12

Review 9.  Hyperhidrosis: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins.

Authors:  Amanda-Amrita D Lakraj; Narges Moghimi; Bahman Jabbari
Journal:  Toxins (Basel)       Date:  2013-04-23       Impact factor: 4.546

10.  Thoracoscopic sympathicotomy for the treatment of intolerable palmar and axillary hyperhidrosis in children is associated with high recurrence rates.

Authors:  Arjan J F P Verhaegh; Michiel Kuijpers; Maartje Boon; Mike J L DeJongste; Wobbe Bouma; Massimo A Mariani; Theo J Klinkenberg
Journal:  Pediatr Dermatol       Date:  2020-07-16       Impact factor: 1.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.